- Home
- INNV vs ALLO Comparison
INNV vs ALLO Comparison
Compare INNV & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INNV
- ALLO
- Stock Information
- Founded
- INNV 2007
- ALLO 2017
- Country
- INNV United States
- ALLO United States
- Employees
- INNV N/A
- ALLO 361
- Industry
- INNV Medical/Nursing Services
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INNV Health Care
- ALLO Health Care
- Exchange
- INNV Nasdaq
- ALLO Nasdaq
- Market Cap
- INNV 373.3M
- ALLO 371.8M
- IPO Year
- INNV 2021
- ALLO 2018
- Fundamental
- Price
- INNV $3.64
- ALLO $1.17
- Analyst Decision
- INNV Sell
- ALLO Strong Buy
- Analyst Count
- INNV 2
- ALLO 10
- Target Price
- INNV $5.00
- ALLO $9.66
- AVG Volume (30 Days)
- INNV 36.1K
- ALLO 2.9M
- Earning Date
- INNV 05-06-2025
- ALLO 05-13-2025
- Dividend Yield
- INNV N/A
- ALLO N/A
- EPS Growth
- INNV N/A
- ALLO N/A
- EPS
- INNV N/A
- ALLO N/A
- Revenue
- INNV $831,683,000.00
- ALLO $22,000.00
- Revenue This Year
- INNV $13.21
- ALLO N/A
- Revenue Next Year
- INNV $10.29
- ALLO $9.07
- P/E Ratio
- INNV N/A
- ALLO N/A
- Revenue Growth
- INNV 12.19
- ALLO N/A
- 52 Week Low
- INNV $2.60
- ALLO $1.09
- 52 Week High
- INNV $6.69
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- INNV 66.17
- ALLO 38.89
- Support Level
- INNV $2.84
- ALLO $1.09
- Resistance Level
- INNV $3.18
- ALLO $1.78
- Average True Range (ATR)
- INNV 0.26
- ALLO 0.14
- MACD
- INNV 0.08
- ALLO -0.03
- Stochastic Oscillator
- INNV 98.95
- ALLO 27.46
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.